Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
New York State Psychiatric Institute |
---|---|
Information provided by: | New York State Psychiatric Institute |
ClinicalTrials.gov Identifier: | NCT00728923 |
Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with SRI treatment, most patients continue to experience significant OCD symptoms, impaired functioning, and diminished quality of life. Recent evidence suggest that a different neurotransmitter, glutamate, may contribute to the symptoms in OCD. Medications that target glutamate hold promise for ameliorating symptoms for those patients continuing to suffer from OCD. In this study we are recruiting patients to receive the drug NPL-2003, which is thought to modulate the neurotransmitter glutamate, added to whatever other OCD medications they are taking in a 12-week open label study.
Condition | Intervention | Phase |
---|---|---|
Obsessive Compulsive Disorder |
Drug: NPL-2003 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Pilot Study of NPL-2003 in Adults With Obsessive-Compulsive Disorder (OCD) |
Estimated Enrollment: | 20 |
Study Start Date: | August 2008 |
Estimated Study Completion Date: | July 2010 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
NPL-2003
|
Drug: NPL-2003
NPL-2003 (5707) daily for 12 weeks
|
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Carolyn I. Rodriguez, M.D., Ph.D. | 212-543-5637 |
United States, New York | |
New York State Psychiatric Institute | Recruiting |
Bronx, New York, United States, 10032 | |
Contact: Carolyn I. Rodriguez, M.D., Ph.D. 212-543-5637 | |
Principal Investigator: Carolyn I. Rodriguez, M.D., Ph.D. |
Principal Investigator: | Carolyn I. Rodriguez, M.D., Ph.D. | Columbia-NYSPI-RFMH |
Responsible Party: | Columbia-NYSPI-RFMH ( Carolyn Rodriguez, M.D., Ph.D. ) |
Study ID Numbers: | 5707 |
Study First Received: | July 31, 2008 |
Last Updated: | August 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00728923 |
Health Authority: | United States: Institutional Review Board |
OCD |
Anxiety Disorders Mental Disorders Obsessive-Compulsive Disorder |
Pathologic Processes Disease |